NCT06886113 - CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial | Biotech Hunter

Enrollment

269

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

February 15, 2028

Conditions

Cardiogenic Shock

Interventions

DEVICE

Conventional circulatory support

Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs

DEVICE

CorVad

Control group treated with Impella CP for a minimum of 48 hrs

Trial Locations (1)

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors

lead

Shenzhen Core Medical Technology CO.,LTD.

INDUSTRY